FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949271110> ?p ?o ?g. }

• W2949271110 endingPage "1043.e1" @default.
• W2949271110 startingPage "1032" @default.
• W2949271110 abstract "Background & AimsThere is no consensus on the best way to integrate biomarkers into inflammatory bowel disease (IBD) research and clinical practice. The International Organization for the Study of Inflammatory Bowel Disease aimed to outline biomarker definitions, categories, and operating properties required for their use in registration trials and clinical practice. Using fecal calprotectin as an example, we provide a framework for biomarker development and validation in patients with IBD.MethodsWe reviewed international society guidelines, regulatory agency guidance documents, and standardized reporting guidelines for biomarkers, in combination with publications on fecal calprotectin levels in patients with IBD. We assessed the validity of fecal calprotectin to serve as a surrogate biomarker of IBD activity and outlined a framework for further validation and development of biomarkers.ResultsNo endpoints have been fully validated as surrogates of risk of disease complications; mucosal healing is the most valid endpoint used to determine risk of disease complications. Fecal level of calprotectin has not been validated as a biomarker for IBD activity because of lack of technical and clinical reliability, assessment of performance when used as a replacement for endoscopy, and assessment of responsiveness to changes in disease states. The level of fecal calprotectin can be used only as a prognostic factor for disease recurrence in patients in remission after medical or surgical treatment.ConclusionsWe reviewed guidelines, regulatory documents, and publications to identify properties required for the development of biomarkers of IBD activity and areas in need of clarification from regulatory agencies and societies. We propose a path forward for research of biomarkers for IBD. There is no consensus on the best way to integrate biomarkers into inflammatory bowel disease (IBD) research and clinical practice. The International Organization for the Study of Inflammatory Bowel Disease aimed to outline biomarker definitions, categories, and operating properties required for their use in registration trials and clinical practice. Using fecal calprotectin as an example, we provide a framework for biomarker development and validation in patients with IBD. We reviewed international society guidelines, regulatory agency guidance documents, and standardized reporting guidelines for biomarkers, in combination with publications on fecal calprotectin levels in patients with IBD. We assessed the validity of fecal calprotectin to serve as a surrogate biomarker of IBD activity and outlined a framework for further validation and development of biomarkers. No endpoints have been fully validated as surrogates of risk of disease complications; mucosal healing is the most valid endpoint used to determine risk of disease complications. Fecal level of calprotectin has not been validated as a biomarker for IBD activity because of lack of technical and clinical reliability, assessment of performance when used as a replacement for endoscopy, and assessment of responsiveness to changes in disease states. The level of fecal calprotectin can be used only as a prognostic factor for disease recurrence in patients in remission after medical or surgical treatment. We reviewed guidelines, regulatory documents, and publications to identify properties required for the development of biomarkers of IBD activity and areas in need of clarification from regulatory agencies and societies. We propose a path forward for research of biomarkers for IBD." @default.
• W2949271110 created "2019-06-27" @default.
• W2949271110 creator A5000165275 @default.
• W2949271110 creator A5004361041 @default.
• W2949271110 creator A5013058329 @default.
• W2949271110 creator A5017140014 @default.
• W2949271110 creator A5025171267 @default.
• W2949271110 creator A5028285577 @default.
• W2949271110 creator A5036870609 @default.
• W2949271110 creator A5042884495 @default.
• W2949271110 creator A5047563454 @default.
• W2949271110 creator A5083726032 @default.
• W2949271110 creator A5084520591 @default.
• W2949271110 date "2019-10-01" @default.
• W2949271110 modified "2023-10-18" @default.
• W2949271110 title "Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases" @default.
• W2949271110 cites W1738875030 @default.
• W2949271110 cites W1814296497 @default.
• W2949271110 cites W1876519312 @default.
• W2949271110 cites W1974217486 @default.
• W2949271110 cites W2010216075 @default.
• W2949271110 cites W2020416845 @default.
• W2949271110 cites W2023078169 @default.
• W2949271110 cites W2040170593 @default.
• W2949271110 cites W2047061163 @default.
• W2949271110 cites W2052776464 @default.
• W2949271110 cites W2054755479 @default.
• W2949271110 cites W2059670411 @default.
• W2949271110 cites W2068828530 @default.
• W2949271110 cites W2080675410 @default.
• W2949271110 cites W2092895549 @default.
• W2949271110 cites W2101619031 @default.
• W2949271110 cites W2105857910 @default.
• W2949271110 cites W2109518441 @default.
• W2949271110 cites W2118812883 @default.
• W2949271110 cites W2120579537 @default.
• W2949271110 cites W2143029465 @default.
• W2949271110 cites W2149170290 @default.
• W2949271110 cites W2155949904 @default.
• W2949271110 cites W2157427654 @default.
• W2949271110 cites W2161661686 @default.
• W2949271110 cites W2166466568 @default.
• W2949271110 cites W2172519764 @default.
• W2949271110 cites W2181706740 @default.
• W2949271110 cites W2433376106 @default.
• W2949271110 cites W2460412619 @default.
• W2949271110 cites W2463239941 @default.
• W2949271110 cites W2523659127 @default.
• W2949271110 cites W2523706394 @default.
• W2949271110 cites W2541771428 @default.
• W2949271110 cites W2551396417 @default.
• W2949271110 cites W2566199716 @default.
• W2949271110 cites W2582253864 @default.
• W2949271110 cites W2583633660 @default.
• W2949271110 cites W2590800515 @default.
• W2949271110 cites W2604490502 @default.
• W2949271110 cites W2605799762 @default.
• W2949271110 cites W2606765556 @default.
• W2949271110 cites W2611198009 @default.
• W2949271110 cites W2611288469 @default.
• W2949271110 cites W2612423848 @default.
• W2949271110 cites W2622582647 @default.
• W2949271110 cites W2726405642 @default.
• W2949271110 cites W2737208830 @default.
• W2949271110 cites W2756793032 @default.
• W2949271110 cites W2766230215 @default.
• W2949271110 cites W2768381772 @default.
• W2949271110 cites W2789404416 @default.
• W2949271110 cites W2790329004 @default.
• W2949271110 cites W2790434969 @default.
• W2949271110 cites W2793170530 @default.
• W2949271110 cites W2794595980 @default.
• W2949271110 cites W2802863404 @default.
• W2949271110 cites W2805227055 @default.
• W2949271110 cites W2809712191 @default.
• W2949271110 cites W2854615164 @default.
• W2949271110 cites W2897151473 @default.
• W2949271110 cites W2912905239 @default.
• W2949271110 cites W2929646270 @default.
• W2949271110 cites W2975668959 @default.
• W2949271110 cites W3020992444 @default.
• W2949271110 cites W4210662453 @default.
• W2949271110 cites W4296224660 @default.
• W2949271110 doi "https://doi.org/10.1053/j.gastro.2019.06.018" @default.
• W2949271110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31228441" @default.
• W2949271110 hasPublicationYear "2019" @default.
• W2949271110 type Work @default.
• W2949271110 sameAs 2949271110 @default.
• W2949271110 citedByCount "44" @default.
• W2949271110 countsByYear W29492711102020 @default.
• W2949271110 countsByYear W29492711102021 @default.
• W2949271110 countsByYear W29492711102022 @default.
• W2949271110 countsByYear W29492711102023 @default.
• W2949271110 crossrefType "journal-article" @default.
• W2949271110 hasAuthorship W2949271110A5000165275 @default.
• W2949271110 hasAuthorship W2949271110A5004361041 @default.
• W2949271110 hasAuthorship W2949271110A5013058329 @default.
• W2949271110 hasAuthorship W2949271110A5017140014 @default.

• next